Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNU6-638P is a pseudogene associated with the U6 small nuclear RNA gene family[2][6]. Pseudogenes are non-functional sequences resulting from genomic duplication or retrotransposition of functional genes. RNU6-638P does not encode active U6 snRNA and is not incorporated into the spliceosome or associated with splicing. Unlike functional U6 snRNA, which plays a catalytic role in spliceosome assembly and intron excision in eukaryotic cells[1][3], pseudogenes such as RNU6-638P serve as evolutionary remnants and do not participate in known biological processes, disease roles, or drug interactions[2][6][5]. There is no evidence supporting its use as a therapeutic target, biomarker, or drug interaction site.\n\nIn summary, RNU6-638P is a non-functional, non-coding RNA pseudogene of U6 snRNA origin and should not be considered a therapeutic target or associated with clinical pharmacology[2][6][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U6 small nuclear 638, pseudogene (RNU6-638P).